Contact us (is on the right)

  1. Company
    1. About
    2. Services
  2. Media
    1. News blog
    2. Meet GCT team
  3. White papers
    1. Region and countries
    2. Therapeutic areas
  4. Services
    1. Site registration
    2. Patient information Center
  5. Website information
    1. Privacy policy
    2. Terms of service
    3. Site map
    4. Employees login

Get in touch

Call us:

Email: info@gctrials.com

Meet us at upcoming industry events

More: Offices, Career at GCT

Patients: Patient information Center

GCT President, Dr. Jeffrey Apter is a keynote speaker at Alzheimersmeet – 2018

We are  pleased to announce that  Dr. Jeffrey T. Apter was invited to be the keynote speaker at Alzheimersmeet – 2018.

The ‘World Congress on Alzheimer’s Research and Therapeutic Advances’ at Hyatt Regency in Dubai, UAE, will be held September 6th and 7th 2018. The main topic of the congress is “A Discussion For Developing Advanced Knowledge on Treatment Mechanisms, Processes and Recovery Methodologies Associated with Alzheimer’s Disease “.

On the Day-1, right after the opening ceremony Dr. Apter is featuring “Current Trends in Disease Modifying/ Preventive Therapies for Alzheimer’s Disease”.  He will share valuable insights on the latest techniques how to reduce AD influence and he will raise questions that will lead to fruitful discussion about what the society can expect in the nearest future in the fight against Alzheimer’s disease.

Being a KOL in Alzheimer’s disease with 40+ years of experience, Dr. Apter has

conducted a couple of hundreds CNS clinical trials and he continues to lead cutting edge psychiatric R&D programmes. Dr. Apter is internationally renowned principal investigator in CNS field. He was recently assigned New Jersey Top Doctor Award 2018.

As GCT President and co-founder, for more than 17 years Dr. Apter shares his valuable expertise in the field of CNS to pharma companies struggling to find a cure to Alzheimer’s disease and to complete all stages of clinical trials. This allows to significantly reduce R&D expenditures for our clients and to avoid puzzles during multinational phase II-III key points.

Interested in finding out more? Sign up for a face-to face meeting at bd@gctrials.com